Factors That Affect the Development of COPD Symptoms

NCT00740337 | Completed DMC

• 1 other identifier: 582
• Study Type: observational
• Target: 82
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic obstructive pulmonary disease (COPD) is the fourth most common cause of death in the United States. There is no cure and the disease gets worse over time. Although it usually occurs in people who smoke cigarettes, researchers do not know exactly how smoking leads to COPD. This study will compare blood and tissue samples from smokers and nonsmokers with and without COPD to determine why some COPD symptoms occur in some people and not others.

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

Chronic Obstructive Pulmonary Disease; COPD; Emphysema; Natural Killer T-cell; Interleukin-13; Innate Immune Signaling

Study Arms (2)

COPD

Participants in this group will be people who have COPD and plan to undergo lung resection surgery at Barnes-Jewish Hospital (BJH).

Control

Participants in this group will be people who do not have COPD and plan to undergo lung resection surgery at BJH.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

People in this study will be invited to participate if they plan to undergo lung resection surgery at BJH.

You may qualify if:

• Ability to read and write in English
• Able to participate in the informed consent process
• Planned lung resection at BJH
• Acceptable pulmonary function tests done at BJH within 1 month of enrollment
• Acceptable chest CT scan done at BJH within 3 years of enrollment

You may not qualify if:

• Pregnant
• Prisoner
• Vulnerable populations
• Clinically significant lung disease other than COPD and the indication for resection (e.g., cystic fibrosis, bronchiectasis, obliterative bronchiolitis, airway lesion)
• Coexisting active chronic inflammatory or collagen vascular disease, immune deficiency of any kind, or previous organ transplant
• Known active hepatitis B, hepatitis C, or HIV/AIDS (not prospectively evaluated)
• Systemic chemotherapy within past 1 month (30 days)
• Hematologic malignancy or thoracic radiation within past year

Sponsors & Collaborators

• Washington University School of Medicine: lead

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Plasma, serum, isolated RNA and DNA, lung tissue

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Emphysema; Rhinitis, Allergic

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Rhinitis; Nose Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Michael J. Holtzman, MD

  Pulmonary and Critical Care, Washington University School of Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 20, 2008
• First Posted: August 22, 2008
• Study Start: October 1, 2007
• Primary Completion: February 1, 2016
• Study Completion: February 1, 2016
• Last Updated: June 18, 2018

Record last verified: 2018-06

Locations

US (1)